GLP-1 Concept Stock Amylyx Soars 247% Year-to-Date: How Much Room Remains for Upside? Sep 2, 2026 Life Science
Kimberly-Clark’s Merger Acquisition Hangs in the Balance? Market Doubts and Potential Opportunities Coexist Sep 1, 2026 Financial Service, Life Science
Ark Invest Goes Against the Grain: Wood Bets on Nvidia and the Gene-Editing Arena Sep 1, 2026 Life Science
Eli Lilly Is on an M&A Spree—Will the $2.88 Billion Merida Deal Be Enough to Diversify? Aug 31, 2026 Life Science
How to Choose Between Two Major Pharmaceutical Themed ETFs? Aug 28, 2026 Financial Service, Life Science
Rasonque’s Lightning Approval Validates Druckenmiller’s Bet on Revolution Medicines Aug 28, 2026 Life Science
Clinical-Stage Biotechnology Company Biohaven Sees Dual Positive Developments During the Week Aug 28, 2026 Life Science
Billionaire Loads Up on Revolution Medicines, the Upside Could Be More Than 7% Aug 26, 2026 Life Science
Beyond Eli Lilly and Novo Nordisk: Overlooked Opportunities in the GLP-1 Race Aug 25, 2026 Life Science
Medicare Part D Subsidy Expires Next Year, Retirees Should Watch for Premium Changes Aug 22, 2026 Life Science
Pharmacy Drag and Consumer Weakness Slow Wal-Mart’s Growth, with E-Commerce and Membership Businesses Becoming Future Highlights Aug 21, 2026 Consumer Goods, Life Science
Moderna Gains Strong Recovery Momentum, Pipeline Breakthroughs and the Long-Term Logic Behind a $10 Billion Market Value Aug 20, 2026 Life Science
Moderna Surges Nearly 60%, But Clinical Win Has Yet to Reverse Financial Slide Aug 19, 2026 Life Science
